Management of dyslipidaemia in patients with comorbidities: facing the challenge: type 2 diabetes mellitus

Type 2 diabetes mellitus typically has the lipid features of elevated trigycerides, reduced HDL-cholesterol (both parts of the metabolic syndrome) and average or slightly elevated LDL-cholesterol. In consequence of hypertriglyceridemia, LDL particles are small and dense and therefore highly atherogenic. Outcome studies reveal that LDL-C lowering drugs have an above-average efficacy in type 2 diabetes as compared with non-diabetic patients. A minor increase of glycaemia in statin trials does not impair the beneficial cardiovascular results. Non-statin lipid lowering drugs do not impair glycaemia. Type 2 diabetes mellitus is now considered a major indication for lipid lowering drugs, thus there is a high value of and no major limitation for those compounds.

Authors

Institutions

Publication Details

Journal
European Heart Journal - Cardiovascular Pharmacotherapy
Published
2025-10-20
DOI
https://doi.org/10.1093/ehjcvp/pvaf076
Primary Topic
Diabetes, Cardiovascular Risks, and Lipoproteins
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Management of dyslipidaemia in patients with comorbidities: facing the challenge: type 2 diabetes mellitus

Juan Tamargo, Dobromir Dobrev, Thomas Schmidt, Bianca Rocca et al.
European Heart Journal - Cardiovascular Pharmacotherapy
Diabetes, Cardiovascular Risks, and Lipoproteins
article

Management of dyslipidaemia in patients with comorbidities: facing the challenge: type 2 diabetes mellitus

Juan Tamargo, Dobromir Dobrev, Thomas Schmidt, Bianca Rocca, Susanne Kaser, Heinz Drexel, Stefan Agewall, Andreas Festa
article en

Abstract

Type 2 diabetes mellitus typically has the lipid features of elevated trigycerides, reduced HDL-cholesterol (both parts of the metabolic syndrome) and average or slightly elevated LDL-cholesterol. In consequence of hypertriglyceridemia, LDL particles are small and dense and therefore highly atherogenic. Outcome studies reveal that LDL-C lowering drugs have an above-average efficacy in type 2 diabetes as compared with non-diabetic patients. A minor increase of glycaemia in statin trials does not impair the beneficial cardiovascular results. Non-statin lipid lowering drugs do not impair glycaemia. Type 2 diabetes mellitus is now considered a major indication for lipid lowering drugs, thus there is a high value of and no major limitation for those compounds.

European Heart Journal - Cardiovascular PharmacotherapyVol. 11(8)
University of Copenhagen (DK), Innsbruck Medical University (AT), Baylor College of Medicine (US), Montreal Heart Institute (CA), Copenhagen University Hospital (DK), Karolinska Institutet (SE), Hospital General Universitario Gregorio Marañón (ES), Landeskrankenhaus Feldkirch (AT), Glanrhyd Hospital (GB), Private University in the Principality of Liechtenstein (LI), Vorarlberg Institute for Vascular Investigation and Treatment (AT), LUM Jean Monnet University (IT), Holbæk Sygehus (DK), West German Heart and Vascular Center Essen (DE), Drexel University (US)
Openalex Percentile: Top 58%
Diabetes, Cardiovascular Risks, and Lipoproteins
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.